253 related articles for article (PubMed ID: 15048614)
1. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
2. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
4. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.
Llerena A; Berecz R; Dorado P; de la Rubia A
J Psychopharmacol; 2004 Jun; 18(2):189-93. PubMed ID: 15260906
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
6. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
Bork JA; Rogers T; Wedlund PJ; de Leon J
J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
[TBL] [Abstract][Full Text] [Related]
7. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio.
Ohara K; Tanabu S; Ishibashi K; Ikemoto K; Yoshida K; Shibuya H
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):347-50. PubMed ID: 12691769
[TBL] [Abstract][Full Text] [Related]
8. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
[TBL] [Abstract][Full Text] [Related]
9. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
11. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
[TBL] [Abstract][Full Text] [Related]
12. The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.
Wink J; Veering BT; Kruit M; Burm AG; Huledal GA; Ekström GY; Stienstra R; van Kleef JW
Anesth Analg; 2008 Jan; 106(1):143-6, table of contents. PubMed ID: 18165569
[TBL] [Abstract][Full Text] [Related]
13. [CYP 2D6 activity profile among patients with depression].
Bidziński A; Koszewska I; Turzyńska D; Kalinowski A; Swiecicki L; Dabrowski M; Torbiński J; Burna-Drazkowic E; Fornal S; Gradzka D; Namysłowska M; Puzyński S; Płaźnik A
Psychiatr Pol; 2004; 38(6):1085-92. PubMed ID: 15779672
[TBL] [Abstract][Full Text] [Related]
14. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
15. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.
Ieiri I; Yamada S; Seto K; Morita T; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
Pharmacopsychiatry; 2003 Sep; 36(5):192-6. PubMed ID: 14571354
[TBL] [Abstract][Full Text] [Related]
16. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
Wennerholm A; Nordmark A; Pihlsgård M; Mahindi M; Bertilsson L; Gustafsson LL
Eur J Clin Pharmacol; 2006 Jul; 62(7):539-46. PubMed ID: 16783563
[TBL] [Abstract][Full Text] [Related]
17. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio.
Ohara K; Tanabu S; Yoshida K; Ishibashi K; Ikemoto K; Shibuya H
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):945-9. PubMed ID: 14499311
[TBL] [Abstract][Full Text] [Related]
18. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
[TBL] [Abstract][Full Text] [Related]
19. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
20. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
